Yasuyuki Suzuki (1), Kazuhiro Goto (1), Atsushi Ishige (1), Yasuhiro
Komatsu (1) and Junzo Kamei (2)
(1) Kampo and Pharmacognosy Laboratories, Tsumura & Co., Ami-machi,
Inashiki-gun, Ibaraki 300-1192, Japan
(2) Department of Pathophysiology & Therapeutics, Faculty of Pharmaceutical
Sciences, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan
Abstract: We evaluated the effects of Gosha-jinki-gan on platelet
aggregation in streptozotocin-induced diabetic rats. Enhanced ADP (2 microM)-induced
aggregation of platelets obtained from diabetic rats was inhibited by a
single treatment with Gosha-jinki-gan (0.3, 1.5 g/kg, p.o.). The anti-platelet
aggregatory effect of Gosha-jinki-gan (1.5 g/kg, p.o.) was attenuated by
simultaneous administration of atropine (1 mg/kg, i.p.) and was abolished
by combination of atropine with Hoe 140 (250 microg/kg x 2, i.p.), a bradykinin
B2 receptor antagonist or L-NAME (10 mg/kg, i.p.), an inhibitor
of nitric oxide-synthase. These results suggested that Gosha-jinki-gan could
improve platelet aggregation in diabetes through increased production of
nitric oxide via bradykinin B2-receptors and muscarinic acetylcholine
receptors.
Keywords: Gosha-jinki-gan, Platelet aggregation, Nitric oxide